

# Utilization of Specialty Blood Products

**Nicole Saviano, MD**

**Medical Director**

**LifeServe Blood Center**

Nicole.Saviano@lifeservebloodcenter.org

319-359-0652



**LifeServe**  
BLOOD CENTER


**YOUR BLOOD. YOUR HOSPITAL. YOUR NEIGHBORS.**

# Objectives

1. Familiarize yourself with the different specialized products
2. Understand when to use



# Products:

- Irradiated Units
  - Washed RBC
  - Volume Reduced Units
  - Granulocytes ASO
  - HLA-Matched Platelets
  - Antigen Negative Units
  - HbS Negative Units
- 

**Slide 3**

---

**AS0**

**Not needed**

Smith, Alex, 2024-11-04T18:39:15.237


# Irradiated Blood Products



# Irradiation of Blood Components



GVHD



DEHP Leaching Investigation

# GVHD:

- Cellular blood components are irradiated to destroy viable T lymphocytes, which may lead to graft vs host disease (GVHD)
- GVHD results when immunocompetent viable lymphocytes in donor product engraft in an immunocompromised host. This engrafted lymphocyte recognizes the recipients' cells as foreign attack the tissues.
- This leads to serious consequences involving liver, GI tract and skin
- Chronic or acute

AS0

AS1



## Slide 6

---

- AS0**      **Not needed**  
Smith, Alex, 2024-11-04T18:39:59.192
- AS1**      **Not needed**  
Smith, Alex, 2024-11-04T18:40:14.757
- AS2**      **Patient's**  
Smith, Alex, 2024-11-04T18:42:02




# Patients at greatest risk include:

- Severely immunosuppressed
- Immunocompromised
- Receiving blood donation via relatives
- Fetuses receiving intra-uterine transfusions





# Irradiation:

- Irradiation inactivates T lymphocytes WITHOUT damaging platelets, RBC and Granulocytes
- Must be labeled "IRRADIATED"
- Expiration date of unit changes to 28 days <sup>ASO</sup> or keeps the original expiration date, whichever comes first
- May be transfused to normal patient if not used by intended recipient

 RAD-SURE®	OPERATOR: _____	DATE: _____
25 Gy INDICATOR	<b>NOT</b>	IRRADIATED
ISP TECHNOLOGIES INC.	LOT NO: _____	EXP: _____

BEFORE IRRADIATION

 RAD-SURE®	OPERATOR: _____	DATE: _____
25 Gy INDICATOR		IRRADIATED
ISP TECHNOLOGIES INC.	LOT NO: _____	EXP: _____

AFTER IRRADIATION @ 25 Gy

**Slide 8**


---

**AS0**


Or keeps the original expiration date, whichever is sooner

Smith, Alex, 2024-11-04T18:42:35.024

# Indications for Irradiation:


- Intrauterine transfusions
  - Donation from blood relatives
  - HLA matched platelets
  - Granulocyte transfusions
  - Hematologic malignancies
  - Hodgkin's lymphoma patients
  - Known or suspected congenital immunodeficiency due to T-cell defects (SCID, DiGeorge)
  - Patients who received purine analog drugs
  - Patients who are receiving alemtuzumab (anti-CD52 monoclonal Ab for tx CLL, aplastic anemia or other hematologic malignancies)
- 

# Comments:

- Irradiation of products should be done as close as possible to time of planned transfusion (risk of hyperkalemia; neonatal patients)
  - Use of irradiated blood components is **not** routinely required for **solid organ transplant patients**
  - There is no indication for irradiation of RBCs or platelets for patients who have HIV
  - Pathogen reduction is equally effective as irradiation in preventing proliferation of donor T lymphocytes for prevention of GVHD (UVA light treatment inactivates DNA replication in cells including DNA in any donor T-lymphocyte)
- 



# GVHD




# Washed Blood Products






# Cell Washer:





# Why Wash?

- Necessary for patients with a diagnosis of IgA deficiency **WITH** Anti-IgA Ab's
  - Necessary if one has suffered REPEATED severe allergic or anaphylactic reactions with previous blood transfusions
  - Recurrent severe allergic reactions not prevented with appropriate premedication
  - Necessary if patient is at risk of SEVERE HYPERKALEMIA, (e.g. neonate) – red blood cells only
- 

# Low IgA and Selective IgA Deficiency

## What is IgA?

IgA is the most common type of antibody  
IgA helps **prevent infection** by complexing with bacterial antigens for removal.

## IgA Deficiency

IgA deficiency is the most common **immunodeficiency** worldwide

Symptoms of IgA deficiency include:

- Increased **gastrointestinal tract infections**
- Recurrent **respiratory tract infections**
- Increased risk of **allergies**
- More frequent **urinary tract infections** or skin infections
- Increased risk of **autoimmune diseases**

## Genetics and IgA deficiency



**IFIH1 gene** - Variants in IFIH1 that decrease IgA are linked to auto immune diseases

**HLA-DQ2.5** - Variants decrease IgA and are linked to celiac disease

**HLA-DRB1\*1501** - Strongly protective against IgA deficiency, however first strong link to MS

## Increasing IgA



• Probiotics - *Bifidobacterium* and *Lactobacillus* strains of Probiotics may increase IgA




• Vitamin A - Used in IgA transport



• Proper sleep - Lack of REM sleep can cause IgA deficiency

# Process of Washing:

- Process involves 3 wash cycles with 0.9% sodium chloride
  - Removes up to 20% of the RBC's and 98% of the plasma
  - 20-30% of decreased platelet functions
  - RBC units should be used within 24 hr after processing; platelets should be used within 4 hr
  - Process takes up to **2 hours** per unit and yields lower quality and quantity of RBC's.
  - Key: Washing units removes plasma proteins, antibodies, K+-electrolytes, free hemoglobin, WBC's, platelets and other micro-aggregates which may cause febrile or urticarial reactions
- 


## Symptoms (1)

85–90% of IgA-deficient individuals are asymptomatic.



◆ The most common symptom of Selective IgA Deficiency is susceptibility to infections including:

- Bronchitis.
- Chronic diarrhea.
- Conjunctivitis.
- Gastrointestinal inflammation.
- Mouth infection.



# Volume Reduced Blood Products





# Volume Reduced Blood Products:

- AKA hyperpacking or hyperconcentrating
- Volume reduction involves the aseptic removal of a portion of the supernatant containing plasma and storage medium additives, following centrifugation.
- Patients in whom fluid status is being aggressively managed (CHF, renal failure) or patients at risk for transfusion associated circulatory overload (TACO) ASO
- Shelf life of volume reduced components is no more than 24 hours if stored at 1-6 C or 4 hours if stored at 20-24C

**Slide 19**


---

**AS0**

I would remove this so people don't get confused with washed products


Smith, Alex, 2024-11-04T18:47:27.171

# GRANULOCYTES






# Granulocytes Overview:


- Indications: neutropenic patient with life-threatening bacterial or fungal infections, without response to antibiotics
  - Bags must be irradiated to avoid GVHD
  - CMV status of donor important as we can not leukoreduce!
  - **\*\*ABO compatible units ONLY \*\***
  - Collected via apheresis after mobilization
  - Efficacy remains unproven
- 

# Granulocytes Indications

- Patients with prolonged disease-related neutropenia:
  - Aplastic anemia
  - Congenital granulocytic deficiency
  - Neonatal sepsis
- Patients with therapy-related neutropenia:
  - Aggressive chemotherapy recipients
  - Bone marrow or hematopoietic stem cell transplant recipients



# Minimal Criteria for Patients:


- Absolute neutrophil count of less than 500 cells/microL
  - Evidence of bacterial or fungal infection/clinical symptoms
    - (+) cultures, proven biopsy, (+) x-ray-infiltrates (pneumonia)
  - Unresponsive to antimicrobial treatment for at least 48 hours
- 

# Granulocyte Collection

- Apheresis: process where only desired cell population is collected
  - Red blood cells, plasma, and other white blood cells are returned
- Should be performed for at least 160 minutes to collect 7-10 L of blood/max granulocyte yield
- Hydroxyethyl starch (HES) is added to donor blood to allow for granulocytes to separate out/ accelerating erythrocyte sedimentation



## Stimulating Factors Administered 24 Hours Prior: Corticosteroids and G-CSF

- Corticosteroids can double the number of circulating granulocytes by mobilizing them from the marginal pool
    - 60 mg of oral prednisone / or 8 mg of dexamethasone
    - Keep in mind donor's medical history (HTN, DM, peptic ulcer disease are contraindicated)
  - Growth factors: G-CSF (Filgrastim/Neupogen)
    - Cytokine/glycoprotein that stimulates the bone marrow to produce stem cells/granulocytes. They are released into the peripheral blood within 2 hours and peak after 12 hours of administration.
  - **NOTE:** In combination, these two drugs increase granulocyte collection to 5 - 10<sup>10</sup> in one administration, compared to steroid administration alone.
- 

# Quality of Granulocytes after G-CSF Stimulation

- Neutrophils collected after the administration of G-CSF have prolonged survival period post-transfusion:
  - Released from bone marrow as an immature population
  - Delayed apoptosis
  - Better respiratory burst
  - Better chemotaxis
  - Better bactericidal activity



# Medication Side Effects

- Headache
- Arthralgia
- Bone pain
- Fatigue
- Insomnia
- Hyperglycemia



# Donor Qualifications

- The willing donors must meet the minimum standards in donor history and physical set by the US FDA:
  - **ABO/RH cross-match compatible to recipient**
    - Difficulty in separating the RBC layer from granulocyte layer of apheresis collection; granulocyte concentrations are usually heavily contaminated with RBCs






# Burden on Donors

- Three visits prior to collection for:
  - 1. Initial screen
  - 2. Medication administration
  - 3. Donation
- Two visits for every subsequent donation from there on after
- Procedure time: 4-5 hours




# Granulocyte Processing

- All granulocyte concentrates should be irradiated to deactivate lymphocytes in product—> avoid transfusion-associated graft versus host disease (GVHD)
  - ex. Immunodeficient/ immunocompromised patients
- Recruit seronegative CMV donors to provide products specifically for seronegative patients
  - we can not leukoreduce these products!
- STORAGE
  - Granulocyte products can only be stored for 24 hours (\*\*shortest shelf life of any product we obtain from donation---apoptosis\*\*)
  - Stored at room temperature (no agitation required)



# Granulocyte Components

- 1 unstimulated donor unit contains minimally  $1 \times 10^{10}$  granulocytes
- 1 stimulated donor unit contains minimally  $4-5 \times 10^{10}$  granulocytes
- You cannot just order casually
- You cannot order STAT



# Granulocyte processing cont..

- Must be transfused within 24 hours:
  - Clinicians, therefore, must order on an “as needed” basis, the day before potential transfusion
  - If the clinician does not use the unit, unit must be disposed of


# Some Complications

- 1. Pulmonary adverse reactions-TRALI-(granulocytes love the lungs)
  - Degrees of cough, dyspnea, hypoxia, chest x-ray changes
- 2. Transfusion-associated GVHD-donors lymphocytes present in the unit amount an immunologic attack against the recipient (can occur immune competent and compromised patients)- rare (irradiate)
- 3. Alloimmunization- antibodies develop to HLA / granulocyte-specific antigens
  - —> reduction in granulocyte survival and abnormal migration





# Variables of Concern:


- There have been difficulties in collecting viable, functional granulocytes
  - It is still unclear what the adequate number of granulocytes are to administer to reach therapeutic levels
    - The optimal therapeutic dose in adults is still unknown;
    - for children it is 10 to 10ml/kg. This may provide adequate numbers of granulocytes per dose
  - Donors must consent to administration of granulocyte stimulating factor; (G-CSF) and Dexamethasone
  - Use of hydroxyethyl starch (HES) —> low Hgb, anaphylactoid reactions, interferes with laboratory tests (elevated serum amylase levels), decreases total protein, calcium, fibrinogen levels
- 

# HLA-Matched Platelets








# HLA Matched Platelets



# HLA matched Platelets:



- Patients who fail to respond to platelet transfusions and are at risk of bleeding (Platelet Refractory)
  - There are immune and non-immune causes of platelet refractory
  - Non-immune causes: DIC, Bleed, Splenomegaly, Fever, Sepsis, Medications
  - Immune causes: autoAb and alloAb
    - Auto-Ab: ITP
    - Allo- Ab: HLA (common) and platelet specific (HPA-mostly HPA1)
- 

# Corrected Count Increment:

CCI=Apheresis Platelet Concentrations

$CCI = (\text{Post-platelet count} - \text{Pre-platelet count}) (\text{Body Surface Area}) / \# \text{ of platelets transfused } (x10^{11})$

**CCI > 7500 (1 Hr) or > 5000 (20hr)**



Platelet refractoriness suspected

Confirmation, 2 or more <4 hr CCI (corrected plt ct) <5000

Rule out non-immune cause (sepsis, splenomegaly, etc)

Immune refractoriness confirmed by platelet antibody screen

Crossmatched platelet units, if identified

If cross-matched ineffective or unavailable, HLA-compatible platelets


Additionally, directed-donor platelets from family members or from donors who previously provided an effective CCI

- HLA sensitization is the most common immune cause of refractoriness and can be diagnosed by demonstration of significant levels of antibodies to class I HLA in the refractory patients' serum
- Poor platelet recovery (1-hour CCI), is usually caused by antibody-mediated destruction






# Serologic Testing on Recipient:

- Recipients blood is drawn
  - Class I & II screening assay is performed to detect the presence/absence of HLA antibodies on platelet transfused
  - If screening assay is positive, a HLA antigen assay is performed to identify the specific HLA antibody present in the serum of the patient
  - Ag negative product is requested as a specialized product
- 


# Prevention of Alloimmunization

- When HLA-Ab are present, supply apheresis platelets from donors whose HLA-A and HLA-B antigens match those of recipient/patient
  - Leukoreduction of products
    - Removes HLA antigen source (WBCs)
  - Minimize donor exposure (use apheresis products)
  - Minimize transfusions
- 


# Antigen Negative/ Antigen Matched Blood Products



# Phenotype- matched (red blood cells)

- For patients who require chronic transfusions (HbS, thalassemia)
  - Phenotypically red blood cell units are “matched” for patient’s Rh and K antigens; (D, C, E, c, e, S, s, Fya, Fyb)
  - Matching is done regardless of patient’s corresponding red blood cell antibodies
  - Phenotype-matched blood decreases rate of red cell alloimmunization from as high as 43% to **2.2%**
- 

# Patients who have developed Antibodies:



1. Perform the patient's phenotype
  2. Strongly consider genotyping the patient if not previously done
  3. Transfuse red cells that are matched for all clinically significant antigens against which antibodies are directed. These patients have demonstrated that they are immunologic responders, therefore are more likely to develop antibodies against additional antigens. Prophylactic matching should include Fy<sup>a</sup>, Fy<sup>b</sup>, Jk<sup>a</sup>, Jk<sup>b</sup>, S and s, in addition to D, C, c, E, e, and K, if possible.
- 




HbS Ag Negative Units






# Indications:






# Sickle Cell Anemia

# Clinical Symptoms and Risks:



# Hemoglobin S- Negative RBC's:

- Indicated for transfusions of patients with HbS/ Sickle cell disease
  - Any infant under four months of age needing an RBC transfusion
  - Overall: helps prevent worsening of:
    - Sickle cell disease
    - Vascular occlusion
    - Decreased oxygen carrying capacity
- 

**Thank You....**

**Questions??**





# References

- Technical Manual, Mark K Fung, Nineteenth Edition, AABB, pg 147
  - Journal of Infectious Disease: Current Status of Granulocytes Transfusion Therapy for Infectious Disease, Kai Hubel, David C. Dale, pg 321-328
  - Journal of Translation Medicine: Granulocyte Transfusions in children and adults with hematological malignancies: benefits and contraversies, Chiara Cugno, Star Deola, Perla Filippini, pg 1-28
  - Science direct: Granulocyte Transfusion: Current Science and Perspectives, Kamille A. West, Cathy Conry-Cantilena, pg 1-19
  - The Blood Group Antigen, Facts Book, Marion E. Reid, Christine Loams-Francis
  - Basic and Applied Concepts of Blood Banking and Transfusion Practices, Paula R. Howard, Chp 5:Section 3 &5, Chp 13, Chp 15
  - Apheresis Principles and Practice, 3<sup>rd</sup> Edition, Robert Weinstein, Jeffrey Winters, Zbigniew M. Szczepiorkowski
  - Modern Blood Banking & Transfusion Practices, Seventh Edition, F.A Davis, Part IV, pg 23, Past III Pg 15
- 